Genetic Engineering
Mutant insulin-like growth factor receptor reduces tumor growth and invasion
Published in Gene Therapy Weekly, July 22nd, 2004
According to published research from Canada, "the receptor for the type 1 insulin-like growth factor (IGF-IR) was identified as a major regulator of the malignant phenotype and a target for cancer therapy. In the present study, a novel IGF-IR mutant consisting of the entire extracellular domain of the receptor (IGFIR933) was genetically engineered and expressed in highly metastatic H-59 murine lung carcinoma cells."
"We show here that the cells expressed a truncated heterotetramer (betam-alpha-alpha-betam) that was secreted into the medium...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-07-22)
More Articles from Gene Therapy Weekly
- Drug Development
Novel lipid-based cochleates drive gene uptake into mammalian cells - Gene Expression Systems
External heat treatment controls gene activation in muscle cells - Metastasis
Flt-1 gene transfer suppresses gastric cancer peritoneal metastasis - Nephropathy
Decoy nucleotides mitigate the formation of diabetic kidney disease - Stem-Cell Research
Genetically modified stem cells reverse neurodegenerative symptoms in mice - Bacterial Infection
C. pneumoniae-induced IFN-gamma dependent on 88-IFN-alpha beta-STAT1 signaling - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
